Osteoporosis medication adherence: Physician perceptions vs. patients' utilization

Bone

Volumn 55, Issue 1, 2013, Pages 1-6

  Curtis, Jeffrey R ^a   Cai, Qian ^b   Wade, Sally W ^c   Stolshek, Bradley S ^d   Adams, John L ^e   Balasubramanian, Akhila ^d   Viswanathan, Hema N ^d   Kallich, Joel D ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b HEALTHCORE INC   (United States)

^c Wade Outcomes Research and Consulting   (United States)

^d AMGEN INC   (United States)

^e RAND CORPORATION   (United States)

Author keywords

Adherence; Bisphosphonates; Compliance; Persistence; Postmenopausal osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCITONIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MEASUREMENT; OPTIMISM; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PHARMACY; PHYSICIAN ATTITUDE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION;

ADULT; AGED; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PHARMACIES; PHYSICIANS; UNITED STATES;

EID: 84876314229     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.03.003     Document Type: Article

References (37)

1. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010, 17:25-54.
2. Burge R., Dawson-Hughes B., Solomon D.H., Wong J.B., King A., Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22:465-475.
3. Johnell O., Kanis J.A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006, 17:1726-1733.
4. Center J.R., Bliuc D., Nguyen T.V., Eisman J.A. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007, 297:387-394.
5. Mackey D.C., Lui L.Y., Cawthon P.M., Bauer D.C., Nevitt M.C., Cauley J.A., Hillier T.A., Lewis C.E., Barrett-Connor E., Cummings S.R. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007, 298:2381-2388.
6. Haentjens P., Magaziner J., Colon-Emeric C.S., Vanderschueren D., Milisen K., Velkeniers B., Boonen S. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010, 152:380-390.
7. Moen M.D., Keam S.J. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011, 28:63-82.
8. PREMARIN® (conjugated estrogens tablets, USP) Available at:. http://labeling.pfizer.com/showlabeling.aspx?id=131.
9. Fletcher S.W., Colditz G.A. Failure of estrogen plus progestin therapy for prevention. JAMA 2002, 288:366-368.
10. Rossouw J.E. Effect of postmenopausal hormone therapy on cardiovascular risk. J Hypertens Suppl 2002, 20:S62-S65.
11. Siris E.S., Selby P.L., Saag K.G., Borgstrom F., Herings R.M., Silverman S.L. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122:S3-S13.
12. Brookhart M.A., Avorn J., Katz J.N., Finkelstein J.S., Arnold M., Polinski J.M., Patrick A.R., Mogun H., Solmon D.H. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007, 120:251-256.
13. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
14. Gold D.T., Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006, 4:21-27.
15. Barrett-Connor E., Ensrud K., Tosteson A.N., Varon S.F., Anthony M., Daizadeh N., Wade S. Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int 2009, 20:463-472.
16. Huizinga M.M., Bleich S.N., Beach M.C., Clark J.M., Cooper L.A. Disparity in physician perception of patients' adherence to medications by obesity status. Obesity (Silver Spring) 2010, 18:1932-1937.
17. Huot L., Couris C.M., Tainturier V., Jaglal S., Colin C., Schott A.M. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 2008, 19:1047-1054.
18. Miller L.G., Liu H., Hays R.D., Golin C.E., Beck C.K., Asch S.M., Ma Y., Kaplan A.H., Wenger N.S. How well do clinicians estimate patients' adherence to combination antiretroviral therapy?. J Gen Intern Med 2002, 17:1-11.
19. Wens J., Vermeire E., Royen P.V., Sabbe B., Denekens J. GPs' perspectives of type 2 diabetes patients' adherence to treatment: a qualitative analysis of barriers and solutions. BMC Fam Pract 2005, 6:20.
20. Huas D., Debiais F., Blotman F., Cortet B., Mercier F., Rousseaux C., Berger V., Gaudin A.F., Cotte F.E. Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Womens Health 2010, 10:26.
21. Copher R., Buzinec P., Zarotsky V., Kazis L., Iqbal S.U., Macarios D. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims. Curr Med Res Opin 2010, 26:777-785.
22. Osteoporosis treatment options expand. Mayo Clin Health Lett 2010, 28:4.
23. Burgener M., Arnold M., Katz J.N., Polinski J.M., Cabral D., Avorn J., Solomon D.H. Older adults' knowledge and beliefs about osteoporosis: results of semistructured interviews used for the development of educational materials. J Rheumatol 2005, 32:673-677.
24. Pickney C.S., Arnason J.A. Correlation between patient recall of bone densitometry results and subsequent treatment adherence. Osteoporos Int 2005, 16:1156-1160.
25. Rossini M., Bianchi G., Di Munno O., Giannini S., Minisola S., Sinigaglia L., Adami S. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006, 17:914-921.
26. Tosteson A.N., Grove M.R., Hammond C.S., Moncur M.M., Ray G.T., Hebert G.M., Pressman A.R., Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med 2003, 115:209-216.
27. Miller N.H. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997, 102:43-49.
28. Hamilton B., McCoy K., Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003, 14:259-262.
29. Kendler D., Kung A.W., Fuleihan Gel H., Gonzalez Gonzalez J.G., Gaines K.A., Verbruggen N., Melton M.E. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004, 48:243-251.
30. Recker R.R., Gallagher R., MacCosbe P.E. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005, 80:856-861.
31. Simon J.A., Lewiecki E.M., Smith M.E., Petruschke R.A., Wang L., Palmisano J.J. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002, 24:1871-1886.
32. Weiss M., Vered I., Foldes A.J., Cohen Y.C., Shamir-Elron Y., Ish-Shalom S. Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 2005, 17:143-149.
33. Lee S., Glendenning P., Inderjeeth C.A. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporos Int 2011, 22:741-753.
34. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:1117-1123.
35. Francis V., Korsch B.M., Morris M.J. Gaps in doctor-patient communication. Patients' response to medical advice. N Engl J Med 1969, 280:535-540.
36. Curtis J.R., Xi J., Westfall A.O., Cheng H., Lyles K., Saag K.G., Delzell E. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009, 47:334-341.
37. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., Wong P.K. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.